220 related articles for article (PubMed ID: 9269835)
1. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67.
Mack L; Kerkvliet N; Doig G; O'Malley FP
Hum Pathol; 1997 Aug; 28(8):974-9. PubMed ID: 9269835
[TBL] [Abstract][Full Text] [Related]
2. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins.
Quinn CM; Ostrowski JL; Harkins L; Rice AJ; Loney DP
Histopathology; 1998 Dec; 33(6):531-6. PubMed ID: 9870147
[TBL] [Abstract][Full Text] [Related]
3. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
[TBL] [Abstract][Full Text] [Related]
4. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein.
Leal CB; Schmitt FC; Bento MJ; Maia NC; Lopes CS
Cancer; 1995 Apr; 75(8):2123-31. PubMed ID: 7697603
[TBL] [Abstract][Full Text] [Related]
5. p53, ErbB2, and TAG-72 expression in the spectrum of ductal carcinoma in situ of the breast classified by the Van Nuys system.
Kanthan R; Xiang J; Magliocco AM
Arch Pathol Lab Med; 2000 Feb; 124(2):234-9. PubMed ID: 10656732
[TBL] [Abstract][Full Text] [Related]
6. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.
Rehman S; Crow J; Revell PA
Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657
[TBL] [Abstract][Full Text] [Related]
7. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
[TBL] [Abstract][Full Text] [Related]
8. Differential distribution of ErbB-2 and pS2 proteins in ductal carcinoma in situ of the breast.
Inaji H; Koyama H; Motomura K; Noguchi S
Breast Cancer Res Treat; 1996; 37(1):89-92. PubMed ID: 8750531
[TBL] [Abstract][Full Text] [Related]
9. Ductal carcinoma in situ of the breast: reproducibility of histological subtype analysis.
Scott MA; Lagios MD; Axelsson K; Rogers LW; Anderson TJ; Page DL
Hum Pathol; 1997 Aug; 28(8):967-73. PubMed ID: 9269834
[TBL] [Abstract][Full Text] [Related]
10. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
Baqai T; Shousha S
Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
[TBL] [Abstract][Full Text] [Related]
11. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
12. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade.
Mommers EC; Leonhart AM; Falix F; Michalides R; Meijer CJ; Baak JP; Diest PJ
J Pathol; 2001 Jul; 194(3):327-33. PubMed ID: 11439365
[TBL] [Abstract][Full Text] [Related]
13. Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast.
Zolota V; Gerokosta A; Melachrinou M; Kominea A; Aletra C; Scopa CD
Anticancer Res; 1999; 19(4B):3269-74. PubMed ID: 10652623
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.
Iwase H; Ando Y; Ichihara S; Toyoshima S; Nakamura T; Karamatsu S; Ito Y; Yamashita H; Toyama T; Omoto Y; Fujii Y; Mitsuyama S; Kobayashi S
Breast Cancer; 2001; 8(2):98-104. PubMed ID: 11342981
[TBL] [Abstract][Full Text] [Related]
15. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast.
Rudas M; Neumayer R; Gnant MF; Mittelböck M; Jakesz R; Reiner A
Eur J Cancer; 1997 Jan; 33(1):39-44. PubMed ID: 9071897
[TBL] [Abstract][Full Text] [Related]
16. Cytological and architectural heterogeneity in ductal carcinoma in situ of the breast.
Quinn CM; Ostrowski JL
J Clin Pathol; 1997 Jul; 50(7):596-9. PubMed ID: 9306942
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis.
Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Chikhlikar PR; Ghosh N; Trivedi TI
Ann Surg Oncol; 2000 May; 7(4):305-11. PubMed ID: 10819372
[TBL] [Abstract][Full Text] [Related]
18. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K
Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370
[TBL] [Abstract][Full Text] [Related]
19. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.
Ringberg A; Anagnostaki L; Anderson H; Idvall I; Fernö M;
Eur J Cancer; 2001 Aug; 37(12):1514-22. PubMed ID: 11506959
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical categorisation of ductal carcinoma in situ of the breast.
Meijnen P; Peterse JL; Antonini N; Rutgers EJ; van de Vijver MJ
Br J Cancer; 2008 Jan; 98(1):137-42. PubMed ID: 18043578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]